Welcome to our dedicated page for Si-Bone SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SI-BONE, Inc. (NASDAQ: SIBN) files a range of reports with the U.S. Securities and Exchange Commission that provide detailed insight into its sacropelvic-focused medical device business. This SEC filings page brings together those documents and pairs them with AI-powered summaries to help interpret the information that matters for SIBN stock.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, SI-BONE discloses its revenue from sacroiliac joint fusion and related sacropelvic procedures, gross margin, operating expenses, net loss, adjusted EBITDA, cash and investments, and other key financial metrics. These filings also describe risk factors, clinical evidence supporting its technologies, and considerations related to reimbursement, supply chain, and the healthcare operating environment.
Current reports on Form 8-K are used by SI-BONE to announce material events such as quarterly financial results, preliminary unaudited revenue and cash figures, and leadership or board changes. For example, recent 8-K filings have referenced press releases on quarterly results, preliminary full-year revenue, and executive transitions, as well as consulting and retirement agreements with senior leaders and directors.
This page also provides access to other SEC documents that may include registration statements and proxy materials, which can address topics such as equity compensation, board composition, and corporate governance. For investors interested in insider activity, Forms 3, 4, and 5 (when filed) detail transactions by directors and officers in SIBN shares.
AI-generated highlights on this platform are designed to make SI-BONE’s filings easier to navigate by surfacing key figures, summarizing management’s discussion of performance, and pointing to sections that discuss sacropelvic technologies, clinical evidence, and reimbursement dynamics. Real-time updates from EDGAR ensure that new 10-K, 10-Q, and 8-K filings for SI-BONE, Inc. are available promptly, while AI summaries help reduce the time required to understand their implications.
SI-BONE, Inc. (SIBN) – Form 4 filing dated 07/07/2025
Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported a routine “sell-to-cover” transaction tied to the vesting of restricted stock units (RSUs) on 07/02/2025. To satisfy withholding taxes, Pisetsky sold an aggregate 3,127 common shares in three market transactions at weighted-average prices between $18.26 – $18.38 per share.
Following the sales, the executive retains 261,681 common shares, which includes 145,043 shares underlying un-settled RSUs. No derivative securities were involved, and the filing states the sales were non-discretionary and solely for tax purposes.
The disposition represents approximately 1.2 % of the executive’s post-transaction holdings and does not alter overall insider ownership meaningfully. There is no indication of strategic intent or change in outlook for SIBN; the filing is considered administratively routine under Section 16 rules.